Bayer Pharmaceuticals implements leadership streamlining amid restructuring efforts. < Back Bayer Pharmaceuticals Shakes Up Leadership Structure Bayer Pharmaceuticals implements leadership streamlining amid restructuring efforts. Bayer Pharmaceuticals , a key player in the pharmaceutical industry, has recently announced significant leadership restructuring aimed at streamlining operations and enhancing efficiency. This strategic move comes amidst ongoing efforts to optimize organizational structure and adapt to evolving market dynamics. The restructuring initiative involves a reshuffling of executive positions within Bayer Pharmaceuticals, with the aim of fostering greater collaboration and alignment across various departments. By consolidating leadership roles, the company seeks to facilitate faster decision-making processes and improve overall agility in responding to market demands. This development follows Bayer's earlier announcement of plans to restructure its pharmaceutical division, focusing on key therapeutic areas and reallocating resources to support innovation and growth. The streamlined leadership team is expected to play a pivotal role in driving these strategic objectives forward. The restructuring efforts underscore Bayer's commitment to remaining competitive in the rapidly evolving pharmaceutical landscape. By simplifying its organizational hierarchy and optimizing leadership functions, the company aims to enhance operational efficiency and accelerate the pace of innovation. In a statement regarding the leadership streamlining, Bayer Pharmaceuticals emphasized its dedication to delivering impactful healthcare solutions and improving patient outcomes. The company remains focused on advancing its pipeline of innovative therapies and strengthening its position as a leader in the pharmaceutical industry. As Bayer Pharmaceuticals continues to navigate the challenges and opportunities presented by the healthcare market, the streamlined leadership structure is poised to facilitate greater agility and effectiveness in pursuing strategic goals. Through ongoing innovation and operational excellence, Bayer remains committed to driving positive change and making meaningful contributions to global healthcare. Author BioFocus Newsroom Previous Next

< Back Who Will Win the 2024 Nobel Prize in Physiology or Medicine? As we approach the 2024 Nobel Prize announcement, we highlight three potential candidates whose research promises to reshape the future of healthcare. The Nobel Prize in Physiology or Medicine is one of the most prestigious honors in science, celebrating breakthroughs that significantly advance human knowledge and improve lives. Established by Alfred Nobel’s will, the prize has recognized extraordinary achievements that have reshaped our understanding of biology and medicine. From the discovery of insulin to the development of mRNA vaccines , laureates have been those whose work has had a profound and lasting impact on global health. Notable figures such as Camillo Golgi, Santiago Ramón y Cajal, and Katalin Karikó have left a legacy through their contributions, continuing to influence medical research and treatment today. As we approach this year’s Nobel Prize announcements, scheduled from October 7 to 14, there is growing anticipation about which groundbreaking achievements will be honored. In this article, we highlight three exceptional researchers who have made substantial impacts on global health: Zhijian Chen, known for discovering the cGAS enzyme; Lotte Bjerre Knudsen, who revolutionized treatments for diabetes and obesity with GLP-1-based therapies; and Carl June, whose development of CAR T-cell therapy has transformed cancer treatment. These three stand out for their significant contributions, making them strong contenders for the 2024 Nobel Prize in Physiology or Medicine. Overview of the Nobel Prize Selection Process The Nobel Prize in Physiology or Medicine is awarded to up to three researchers whose work has profoundly influenced human health and medical science. The selection process is confidential and follows several steps. Each year, the Nobel Committee sends over 3,000 invitations to scientists, academics, and past laureates to submit nominations. These nominations are reviewed rigorously, leading to a shortlist, after which the committee consults experts in the relevant fields. Once the committee has made its recommendations, the Nobel Assembly at the Karolinska Institutet votes on the final laureates, a decision kept secret until the official announcement in early October. This high level of confidentiality, with nomination records sealed for 50 years, adds to the prestige and mystique of the Nobel Prize. This year, amid a wealth of potential nominees, three researchers—Chen, Knudsen, and June—stand out for their groundbreaking contributions in immunology, metabolic disorders, and cancer treatment. Zhijian "James" Chen, Ph.D.: Redefining Immunology Dr. Zhijian Chen's discovery of the cyclic GMP-AMP synthase (cGAS) enzyme is a revolutionary finding that has significantly deepened our understanding of the immune system’s response to foreign DNA. His work, which identified the cGAS-STING pathway, provides critical insights into how the body defends itself against viral infections, cancer, and even autoimmune diseases. Before Chen’s discovery, scientists lacked a clear explanation of how the immune system detected cytosolic DNA, especially from pathogens or damaged cells. Chen's breakthrough lies in the mechanism by which the cGAS enzyme recognizes foreign DNA in the cytoplasm—a signal that DNA is outside its normal place in the nucleus or mitochondria. When cGAS detects this DNA, it synthesizes cyclic GMP-AMP (cGAMP), a second messenger that binds to and activates the STING (Stimulator of Interferon Genes) protein. This activation triggers a cascade of immune responses, leading to the production of type I interferons and pro-inflammatory cytokines, which play a critical role in fighting infections and eliminating cancerous cells. Implications in Autoimmune Disease and Cancer One of the most significant aspects of Chen’s discovery is its dual role in fighting diseases. While the cGAS-STING pathway is essential for immune defense, its overactivation can lead to autoimmune diseases such as systemic lupus erythematosus (SLE), where the immune system mistakenly attacks healthy cells. Understanding this balance has allowed researchers to develop cGAS inhibitors that could prevent excessive immune responses in conditions like lupus and arthritis. Early-stage research has already shown promise in animal models, offering hope for new treatments for chronic inflammatory diseases. At the same time, the therapeutic potential of activating the cGAS-STING pathway in cancer immunotherapy is also being explored. STING agonists , which stimulate this pathway, are currently in clinical trials to enhance the immune system’s ability to detect and destroy cancer cells. When combined with other treatments such as immune checkpoint inhibitors, these drugs could significantly improve outcomes for cancer patients, making tumors more susceptible to immune system attacks. Ongoing Research and Recognition Dr. Chen’s discovery has opened the door to a new field of research, with pharmaceutical companies developing drugs that either inhibit or activate the cGAS-STING pathway, depending on the condition being treated. Researchers are also exploring this pathway’s role in infectious diseases, including tuberculosis and herpes, where boosting immune responses could lead to better treatments. In recognition of his groundbreaking work, Dr. Chen was awarded the 2024 Albert Lasker Basic Medical Research Award, a significant honor often considered a precursor to the Nobel Prize. His research has reshaped the field of immunology and continues to guide the development of therapies for a wide range of diseases, including autoimmune disorders, cancer, and infectious diseases. Lotte Bjerre Knudsen: Revolutionizing Metabolic Disease Treatment Lotte Bjerre Knudsen’s work on GLP-1-based therapies has transformed the treatment of two of the world’s most widespread chronic diseases: type 2 diabetes and obesity. As a pharmaceutical scientist at Novo Nordisk , Knudsen was instrumental in translating the hormone GLP-1 (glucagon-like peptide-1) into treatments that have dramatically improved the lives of millions of patients worldwide. GLP-1: The Science Behind the Treatment GLP-1 is a hormone that the gut releases in response to eating. It plays a vital role in regulating blood sugar by stimulating insulin production, inhibiting glucagon release, and slowing gastric emptying, which leads to a feeling of fullness. While GLP-1 was known to have potential therapeutic benefits, its natural form is rapidly degraded in the body, limiting its effectiveness. Knudsen and her team overcame this challenge by developing long-acting GLP-1 analogs, such as liraglutide and semaglutide, which can last much longer in the bloodstream. Liraglutide , which was first approved for the treatment of type 2 diabetes, later became a groundbreaking treatment for obesity. Semaglutide, a newer drug with a longer half-life, allows for weekly dosing and has shown even greater success in managing both blood sugar levels and inducing weight loss. In clinical trials, patients using semaglutide experienced weight loss averaging 15% of their body weight, an outcome that far surpasses previous obesity treatments. Expanding Beyond Diabetes and Obesity Beyond its impact on diabetes and obesity, GLP-1 receptor agonists have shown promising cardioprotective benefits, significantly reducing the risk of heart attack and stroke in patients with diabetes. This dual action on both metabolic and cardiovascular health has made GLP-1 therapies a cornerstone in treating these chronic conditions. Knudsen’s research is now influencing the treatment of other conditions linked to metabolic dysfunction, such as nonalcoholic steatohepatitis (NASH) and chronic kidney disease. Emerging studies also suggest that GLP-1 receptor agonists may have anti-inflammatory effects, opening new possibilities for treating inflammatory diseases like asthma and NASH, further broadening the therapeutic reach of these drugs. Clinical Impact and Recognition The impact of GLP-1-based therapies on patient outcomes has been nothing short of transformative. Both liraglutide and semaglutide have become essential tools in managing not only diabetes and obesity but also improving overall health outcomes. Recognizing her contributions, Knudsen was awarded the 2024 Lasker~DeBakey Clinical Medical Research Award. Her work continues to influence the future of chronic disease management, with potential applications extending well beyond metabolic disorders. Carl June, M.D.: Transforming Cancer Treatment with CAR T-Cell Therapy Dr. Carl June has revolutionized cancer treatment with his development of CAR T-cell therapy, a type of immunotherapy that has dramatically improved outcomes for patients with certain types of cancer. This innovative therapy uses the body’s immune system to target and destroy cancer cells, particularly in hematologic cancers such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. The Science of CAR T-Cell Therapy CAR T-cell therapy involves collecting a patient’s T cells—a type of white blood cell that plays a key role in the immune response—and genetically modifying them to express chimeric antigen receptors (CARs). These receptors are engineered to recognize specific antigens on the surface of cancer cells. Once the modified T cells are re-infused into the patient, they multiply and actively seek out and destroy cancer cells. In clinical trials, CAR T-cell therapy has shown unprecedented success. For instance, in patients with relapsed or refractory ALL, complete remission rates as high as 83% have been observed. The first FDA-approved CAR T-cell therapy, Kymriah (tisagenlecleucel), has provided life-saving options for patients who previously had few or no effective treatments. Challenges and Future Applications Despite its success, CAR T-cell therapy is not without challenges. The therapy can cause severe side effects, including cytokine release syndrome (CRS) and CAR T-cell-related encephalopathy syndrome (CRES). CRS results from an overactivation of the immune system, while CRES affects the central nervous system. Managing these side effects has required the development of new protocols, including the use of tocilizumab to treat severe CRS. Dr. June and his team are now working on expanding the use of CAR T-cell therapy beyond hematologic cancers to treat solid tumors, which are more challenging due to the complex tumor microenvironment. Innovative approaches, such as armored CAR T cells that secrete immune-enhancing proteins, are being tested in early-stage clinical trials for cancers like pancreatic and ovarian cancer. Recognition and Global Impact For his pioneering work, Dr. June received the 2024 Breakthrough Prize in Life Sciences, one of the most prestigious awards in science. His contributions have not only saved countless lives but also laid the foundation for future breakthroughs in cancer immunotherapy. As research continues, CAR T-cell therapy has the potential to become a more widespread treatment for both blood and solid tumors, offering hope to even more patients in the years to come. A New Era in Medicine: Conclusion and Broader Implications Zhijian Chen, Lotte Bjerre Knudsen, and Carl June represent three of the most important scientific advancements in recent history. Despite their work spanning diverse areas—immunology, metabolic disease, and cancer therapy—all three researchers have fundamentally changed how we approach disease treatment. Their contributions mark a shift towards precision medicine, where treatments are increasingly personalized and tailored to specific biological mechanisms. Dr. Chen’s discovery of the cGAS-STING pathway has provided new opportunities to treat autoimmune diseases, cancer, and infections by fine-tuning the immune response. Knudsen’s GLP-1-based therapies have not only transformed diabetes and obesity treatment but also paved the way for future therapies targeting related metabolic disorders and chronic conditions. Carl June’s CAR T-cell therapy has redefined cancer treatment, particularly for patients with previously untreatable blood cancers, and holds promise for solid tumors. It’s important to note that this is just our take on who might be among the strongest contenders for the 2024 Nobel Prize in Physiology or Medicine. The field of biomedical research is rich with talent, and there are countless other researchers whose extraordinary work deserves recognition. No matter who is ultimately awarded the prize, it’s certain that their contributions to science and healthcare will be profound and deserving of this prestigious honor. The global impact of the work by these three scientists is clear. From reducing the burden of chronic diseases like diabetes and obesity to offering life-saving cancer treatments, their breakthroughs are already improving healthcare outcomes for millions of patients. As their therapies continue to evolve, the potential to scale these treatments for broader access promises even greater global health benefits. Their collective achievements underscore the ripple effect of innovation in science: each discovery builds on existing knowledge, opening new pathways for research and treatment. Whether targeting the immune system, metabolic dysfunction, or cancer cells, the work of Chen, Knudsen, and June showcases the power of modern medical science to address some of the most complex challenges in healthcare. As we await the 2024 Nobel Prize announcements, the contributions of these researchers highlight a future where precision, personalized treatments will dominate the medical landscape, providing more effective and individualized care for patients across the globe. Whoever the winners may be, their contributions to medicine and science will be a testament to the brilliance of today’s researchers. Stay tuned—these innovations represent just the beginning of what's possible in the rapidly evolving field of medical science. Read our breakdown of the science behind the 2023 Nobel Prize for Medicine winners here . Author Ramya Nadig , freelance contributor Previous Next

< Back Double the Benefit: GLP-1 Receptor Agonists for Parkinson's Disease Research finds that GLP-1 receptor agonists can slow the progression of Parkinson’s Disease symptoms. Since the first GLP-1 receptor agonist drug was approved by the FDA in 2005 , GLP-1 receptor agonists have risen to fame as a class of drugs approved for the treatment of Type 2 Diabetes. They work by mimicking the effects of the gut hormone glucagon-like peptide-1 (GLP-1), helping regulate blood sugar levels. However, researchers believe they might also have neuroprotective effects and are exploring their potential use in treating Parkinson’s disease (PD). This could be a significant step forward in the treatment of PD – the second most common neurodegenerative disease. Some studies suggest that there is a connection between Parkinson’s disease and dysregulated insulin signalling and that insulin resistance might play a role in dopamine degeneration. Moreover, abnormal glucose metabolism has been observed in various brain regions of Parkinson’s patients, which has been linked to the progression of their motor symptoms. Notably, individuals with Type 2 Diabetes have been found to have an increased risk of developing Parkinson’s. Lixisenatide and exenatide are examples of GLP-1 receptor agonists being tested in Parkinson's patients. These drugs have shown the potential to slow the progression of motor disability caused by Parkinson’s, offering a glimmer of hope for managing this progressive disease. Research published in NEJM unveils new potential for this class of drugs. The LIXIPARK study group, based in France, has published results from a clinical trial that provides further evidence of the connection between Parkinson’s and GLP-1 receptor agonists. They recruited participants whose Parkinson's had been diagnosed for less than three years and showed no motor complications. The trial participants were then split into two groups: one group was given Parkinson’s medication and a placebo, and the other was given Parkinson’s medication plus a daily lixisenatide injection for one year. Through each stage of the study, the participants' motor symptoms were scored on the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III, a disease severity scale. After 12 months, the results revealed that those who received lixisenatide had reduced progression of motor disability compared to the group that received the placebo. How does it work? Due to the complex etiology of Parkinson’s disease, the exact mechanism of action is not clearly understood. However, in vivo and in vitro studies have shown that GLP-1 RAs impact several pathways involved in the development of Parkinson's disease. These include protein misfolding and aggregation, defects in the ubiquitin-proteasome system and aggregation, inflammation, impaired oxidative stress, and mitochondrial dysfunction. In addition, GLP-1 receptors are expressed not only in the gastrointestinal tract and kidneys but also in the brain regions affected by Parkinson’s, such as the basal ganglia and substantia nigra, making them a promising therapeutic target for the disease. Data from several studies have demonstrated a connection between the ability of GLP-1 receptor agonist drugs, including liraglutide and semaglutide, to cross the blood-brain barrier and their neuroprotective effects. Further evidence from animal models of PD and preclinical studies has demonstrated that this class of drugs can restore dopamine levels, prevent dopamine loss, reduce neuronal degeneration, and improve both motor and non-motor symptoms of PD. It's important to note that while the initial research is promising, more studies are needed to fully understand the effectiveness and long-term impact of GLP-1 receptor agonists in treating Parkinson's disease. However, this new avenue of investigation offers a chance to improve the lives of Parkinson’s patients and potentially slow the progression of this debilitating disease. Author Mariam Zaki , freelance contributor Previous Next

< Back 5th – 7th November, 2024 New York, NY BioFuture BioFuture is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health. Participate in candid, unfiltered discussions. At this year’s summit, we’ll explore the exciting convergence between rapidly evolving fields including biopharma, digital medicine, big data, AI, healthcare systems, payors, and more. The coming decade will dramatically accelerate the transformation of the healthcare ecosystem. This year’s event will be a melting pot of cross-industry ideas and insights that fuse the swiftly developing fields of biopharma, digital medicine, big data, artificial intelligence, healthcare systems, insurance providers, and beyond. Previous Register now Next

Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy. < Back Vertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy. Alyftrek builds on the success of previous cystic fibrosis transmembrane conductance regulator (CFTR) modulators, providing a novel option for patients ages six and older with at least one responsive CFTR mutation, including 31 mutations previously untreatable by existing modulators. Achieving FDA approval here is a testament to Vertex’s commitment to addressing the underlying causes of CF and expanding treatment access. A New Standard in CF Treatment For the first time, patients have access to a CFTR modulator with once-daily dosing—a feature addressing a significant unmet need for easier treatment regimens. This advancement could improve medication adherence and overall quality of life for individuals managing the daily demands of CF. The therapy also expands the reach of CFTR modulation, enabling treatment for approximately 150 patients in the U.S. who previously lacked viable options. In clinical trials, Alyftrek demonstrated non-inferiority to Trikafta in improving lung function (measured as ppFEV1) and showed statistically significant reductions in sweat chloride levels, a biomarker of CF disease severity. These findings underscore Alyftrek’s potential to set a new benchmark for effective CF care. Supporting the Broader CF Community With over 92,000 people globally affected by CF, the need for innovative treatments remains urgent. CF is a progressive, multi-organ disease caused by defective or missing CFTR proteins due to genetic mutations. This dysfunction leads to thick, sticky mucus in the lungs and other organs, driving chronic infections, progressive damage, and premature death. Vertex has steadily worked to mitigate these impacts, with its CFTR modulators now treating two-thirds of eligible CF patients worldwide. Alyftrek’s approval follows the most comprehensive Phase 3 trial program in CF to date, spanning more than 1,000 patients across over 20 countries. The results reinforce Vertex’s leadership in developing therapies that not only improve lung function but also address systemic biomarkers like sweat chloride. The therapy’s safety profile was consistent with other CFTR modulators, making it a well-tolerated option for a wide range of patients. The Path Ahead While Alyftrek’s FDA approval is a milestone for the U.S., Vertex’s ambition extends globally. Regulatory submissions are underway in Europe, the U.K., Canada, and other regions, reflecting a commitment to delivering life-changing therapies to patients worldwide. The introduction of Alyftrek’s reflects the progress made in CF research, yet challenges remain. Median life expectancy for CF patients still hovers in the 30s, underscoring the ongoing need for innovation. Alyftrek’s offers hope not only through its expanded reach but also through its potential to ease treatment burdens, allowing patients to focus more on their lives and less on their disease. Alyftrek’s enters the CF market at a list price of $370,269 per year, a 7% premium over Trikafta’s annual cost. While its clinical benefits and more convenient dosing are expected to drive patient transitions, analysts predict a slower adoption curve compared to Trikafta’s groundbreaking launch in 2019. Early adopters are likely to include patients experiencing suboptimal outcomes with Trikafta, estimated to comprise 20-30% of current users. While Alyftrek’s approval underscores Vertex’s dominance in CF therapeutics—a franchise projected to exceed $10 billion in annual sales—the company faces investor scrutiny over its pain candidate, suzetrigine . This nonaddictive alternative to opioids has blockbuster potential, but disappointing Phase 2 data has cast doubt on its near-term prospects, overshadowing Alyftrek’s launch. Conclusion Vertex’s approval of Alyftrek highlights the company’s dedication to transforming CF care. With expanded mutation coverage, improved dosing convenience, and strong clinical outcomes, Alyftrek is poised to enhance the lives of thousands of patients. As Vertex continues to lead in CF innovation, therapies like Alyftrek signal a brighter future for the CF community. Author BioFocus Newsroom Previous Next

< Back Monkeypox Outbreak: Global Health Emergency Declared by WHO The World Health Organisation (WHO) declares global health emergency. Read on to learn more, including insight around the vaccine development process. Health authorities around the world are ramping up efforts to contain a rapidly spreading outbreak of monkeypox. The World Health Organization (WHO) has declared the outbreak a global health emergency, signaling the urgent need for international coordination and response. What is Monkeypox? Monkeypox is a rare viral disease, typically found in remote parts of Central and West Africa, that has recently been spreading to other regions. The virus is similar to smallpox, although generally less severe. It is transmitted to humans through close contact with an infected person or animal, as well as through contaminated materials. Symptoms and Transmission The initial symptoms of monkeypox are similar to those of other viral infections, including fever, headache, muscle aches, and fatigue. After a few days, patients typically develop a rash that starts on the face and spreads to other parts of the body. The rash goes through several stages, eventually forming scabs that fall off. Transmission occurs primarily through direct contact with the bodily fluids or lesions of an infected person or animal. Human-to-human transmission can also occur through respiratory droplets, although this requires prolonged face-to-face contact. The recent outbreaks suggest that transmission may also be occurring through other means, including sexual contact, which has raised concerns among public health officials. The Scope of the Outbreak Since the first cases were reported earlier this year, monkeypox has spread to multiple countries outside Africa, including the United States, Canada, and several European nations. The outbreak is unusual because monkeypox has rarely been seen outside of Africa in the past. As of now, there are thousands of confirmed cases in over 70 countries, prompting the WHO to declare the situation a global emergency. This designation is intended to mobilize resources, coordinate international efforts, and increase awareness and surveillance of the virus. International Response Governments and health organizations are mobilizing resources to combat the spread of monkeypox. Currently, vaccines originally developed for smallpox, such as the JYNNEOS and ACAM2000 vaccines, are being used to combat the spread of monkeypox due to the viruses' similarities. These vaccines have been deployed to high-risk groups, including healthcare workers and close contacts of confirmed cases, as part of the global response to the outbreak. While these vaccines are effective in preventing monkeypox, supply constraints and distribution challenges have been noted, prompting efforts to increase production and expand access. Research is ongoing to develop more targeted vaccines and treatments specifically for monkeypox. Public health campaigns are being launched to educate the public about the symptoms of monkeypox, how it is transmitted, and the importance of early detection and isolation of cases. Authorities are also urging people to avoid close contact with infected individuals and to practice good hygiene. Monkeypox Vaccine Development Developing a specific vaccine for monkeypox could take several years, depending on various factors, such as the urgency of the public health need, the success of clinical trials, and regulatory approvals. Typically, the vaccine development process involves multiple phases: Preclinical Research: This involves laboratory and animal studies to understand the virus and identify potential vaccine candidates. This stage could take several months to a few years. Clinical Trials: Clinical trials are conducted in three phases to test the vaccine's safety and efficacy in humans. Each phase can take several months to years: Phase I: Small groups of volunteers test the vaccine for safety and dosage. Phase II: Larger groups are tested to further evaluate safety and effectiveness. Phase III: Large-scale trials are conducted to confirm efficacy and monitor for adverse reactions. Regulatory Review and Approval: Regulatory bodies, such as the FDA in the United States or the EMA in Europe, review the trial results. This process can take several months to over a year, depending on the urgency and availability of data. Manufacturing and Distribution: Scaling up production to meet global demand can take additional months to years, depending on manufacturing capacity and supply chain logistics. Given these factors, producing a monkeypox-specific vaccine could realistically take several years. However, as seen with COVID-19 vaccines, expedited processes can shorten this timeline if there is an urgent public health need. The COVID-19 vaccine development process was condensed from somewhere in the region of 10 years to just 10 months. What’s Next? The declaration of a global health emergency highlights the seriousness of the monkeypox outbreak and the need for a coordinated global response. While the virus is not as easily transmissible as COVID-19, the potential for further spread remains a concern, particularly in regions with limited healthcare infrastructure. Research into the virus, its transmission, and potential treatments is ongoing, with scientists racing to understand the virus better and develop effective countermeasures. In the meantime, health officials emphasize that public awareness and preventive measures are crucial in controlling the outbreak. As the situation continues to evolve, updates from health authorities and ongoing public health efforts will be critical in managing and eventually containing the spread of monkeypox. Author BioFocus Newsroom Previous Next

Join the BioFocus mailing list to receive industry targeted updates and popular news stories direct to your inbox. Join our mailing list Stay up to date with BioFocus by joining our mailing list. Receive industry updates and popular news stories direct to your inbox. You can also reach out to us via email or follow us on LinkedIn. Email info@bio-focus.co.uk Social Media First name Last name Email Company name Industry Job function Job title Country Key areas that are of interest to your work/research or any questions that you would like to ask the BioFocus team. I acknowledge and agree to the use of my contact information to receive messages about offerings by BioFocus, its brands, affiliates and/or third-party partners, consistent with the BioFocus Privacy Policy View privacy policy. Submit Thanks for submitting.

Atelerix Launches STORganoid: Cryo-Free Ambient-Temperature Preservation for Organoids and Spheroids. < Back Atelerix Launches STORganoid: Cryo-Free Ambient-Temperature Preservation for Organoids and Spheroids Atelerix Launches STORganoid: Cryo-Free Ambient-Temperature Preservation for Organoids and Spheroids. UK biotech Atelerix has launched STORganoid™, a first-of-its-kind ambient-temperature preservation solution for organoids and spheroids. The product enables complex 3D cell models to be stored and shipped over extended periods without cryopreservation, cold chain logistics, or compromised viability, removing a long-standing bottleneck in the global adoption of New Approach Methodologies (NAMs). The Cold Chain Problem Holding Back Organoid Research Organoids and spheroids are among the most predictive tools available in drug discovery and disease modelling. But despite their scientific value, their fragility has made reliable distribution a persistent challenge. These complex 3D cell models are highly sensitive to temperature fluctuations, meaning conventional cryopreservation and hypothermic storage methods can damage structural integrity, reduce viability, and compromise reproducibility. The result: organoid-based research has largely been confined to specialist laboratories with the infrastructure to generate and maintain their own cultures on-site. For global pharmaceutical teams, contract research organisations, and academic collaborators, transferring high-quality organoid models between sites has remained costly, logistically complex, and scientifically risky. How STORganoid Works: Hydrogel Encapsulation at Ambient Temperature STORganoid is built on Atelerix's proprietary hydrogel encapsulation technology. Organoids and spheroids are embedded within a soft hydrogel matrix that stabilises cell membrane integrity and maintains viability at room temperature, eliminating the need for dry ice, liquid nitrogen, or refrigerated transport. The product is designed to deliver models in an assay-ready format, meaning research teams can move directly from receipt to experimental work. There is no need for the lengthy culture recovery protocols that typically add days to organoid workflows. For multi-site studies and inter-laboratory collaborations, this represents a significant reduction in both lead times and logistical overhead. Supporting the Broader Adoption of New Approach Methodologies (NAMs) Regulatory momentum behind NAMs, including organoids, microphysiological systems, and other human-relevant in vitro models, has accelerated in recent years. Agencies including the US FDA and the European Medicines Agency have issued guidance frameworks encouraging the integration of these approaches into preclinical safety and efficacy testing. However, practical standardisation across the sector has lagged, in part because reliable organoid distribution at scale has never been solved. A cryo-free, ambient-temperature preservation solution like STORganoid could play a meaningful role in closing that gap, enabling the reproducibility studies and reference sample programmes that support broader regulatory acceptance of NAMs. Steve Swioklo, CSO and Co-founder of Atelerix, said: "STORganoid addresses one of the key barriers to broader adoption of these highly predictive cell-based models by freeing them from the constraints of specialised laboratory environments and lengthy culture protocols. We are proud to be contributing to the harmonisation and accessibility of new approach methodologies, helping to bring cutting-edge science closer to real-world application." Applications Across Drug Discovery, Disease Modelling, and Personalised Medicine STORganoid is designed to support a wide range of life science applications, including: Drug discovery and toxicology screening, where reproducible organoid assays are increasingly required by sponsors and regulators Disease modelling in oncology, gastroenterology, and rare disease research Personalised medicine programmes that depend on rapid transfer of patient-derived organoid models between clinical and research settings Cell therapy workflows requiring reliable biosample logistics across global sites A Scalable Solution for the Growing Organoid Market STORganoid expands Atelerix's portfolio of fresh biosample preservation products, applying the company's core hydrogel platform to the fast-growing organoid and cell therapy markets. The product is positioned as a scalable commercial solution aligned with rising demand for standardised, distribution-ready 3D cell models, and is expected to underpin new partnerships and more efficient global distribution models for organoid-based research tools. STORganoid is available now from Atelerix. For technical specifications, partnership enquiries, or to request a sample, visit atelerix.com. Author BioFocus Newsroom Previous Next

Read our run down of the cutting-edge biotech industry trends revolutionizing the life science industry. < Back The 10 Biotech Industry Trends Shaping the Future Read our run down of the cutting-edge biotech industry trends revolutionizing the life science industry. The 10 Biotech Industry Trends Shaping the Future Developments in biotechnology sit at the cutting-edge of science and the start-line of industrial revolutions. A new biotech innovation can transform human society. Around six thousand years ago, Homo sapiens harnessed the biological processes of microorganisms to make bread and alcohol. Today, biotechnology connotes a far more advanced manipulation of biological processes; indeed, we are now modifying DNA in highly specific ways to genetically engineer therapeutics that improve lives around the world. From providing solutions to food security challenges through to developing new and improved therapeutic drugs, biotechnology has revolutionized human society. Here, we pick out the 10 key biotech trends that look set to further propel the life science industry, and society, forward. 1. Gene editing revolution Gene editing technologies like CRISPR-Cas9 continue to revolutionize biotech, offering precise and efficient methods for editing genetic material, with applications ranging from disease treatment to agricultural enhancement. One notable example is the treatment of sickle cell disease using CRISPR-Cas9 gene editing. In 2019, researchers at Stanford University used CRISPR to correct the genetic mutation responsible for sickle cell disease in human stem cells, paving the way for potential gene therapies to treat this inherited blood disorder. 2. Personalized medicine Advancements in genomics and bioinformatics enable the development of personalized medicine tailored to individual genetic profiles, enhancing treatment efficacy and minimizing adverse effects. The drug Herceptin (trastuzumab) is often regarded as the ‘poster child’ for personalized medicine in oncology. Herceptin specifically targets cancer cells that overexpress the HER2 protein, which is present in about 20% of breast cancer patients. By identifying patients with HER2-positive breast cancer through genetic testing, physicians can prescribe Herceptin only to those women with these types of tumors, leading to improved treatment outcomes. 3. Immunotherapy breakthroughs Immunotherapy, particularly CAR-T cell therapy, is making strides in cancer treatment by harnessing the body's immune system to target and destroy cancer cells, offering promising outcomes for patients. CAR-T cell therapy has demonstrated remarkable success in treating certain types of blood cancers. Novartis's Kymriah (tisagenlecleucel) and Gilead's Yescarta (axicabtagene ciloleucel) are two FDA-approved CAR-T cell therapies that reprogram a patient's own immune cells to target and eliminate cancer cells, offering new hope to patients with refractory or relapsed leukemia and lymphoma. 4. RNA-based therapeutics RNA-based therapies, including mRNA vaccines and RNA interference (RNAi) therapies, are gaining traction for their potential to target a wide range of diseases, from infectious diseases to genetic disorders. The mRNA COVID-19 vaccines developed by Pfizer-BioNTech and Moderna represent a groundbreaking application of RNA-based technology. These vaccines use synthetic mRNA to instruct cells to produce a viral protein, triggering an immune response that protects against SARS-CoV-2 infection. The rapid development and successful deployment of these vaccines exemplify the potential of RNA-based therapeutics. 5. Bioprinting innovations 3D bioprinting technologies are advancing rapidly, allowing the fabrication of tissues and organs for transplantation, drug testing, and regenerative medicine applications. A new era of tissue engineering is emerging as a result of this technology. In 2019, researchers at Tel Aviv University successfully 3D bioprinted a heart using human cells and a biocompatible scaffold. This achievement marked a significant milestone in tissue engineering and regenerative medicine, demonstrating the feasibility of creating complex organs for transplantation using bioprinting technology. In the bioprocessing industry, a recent study demonstrated how 3D printing of a bioreactor holds immense promise for advancing the efficiency of upstream bioprocessing. 6. Microbiome research Understanding the human microbiome's role in health and disease is a burgeoning field, with implications for developing novel therapeutics, diagnostics, and dietary interventions to modulate microbial communities. The development of microbiome-based therapeutics for gastrointestinal conditions is exemplified by the success of fecal microbiota transplantation (FMT) in treating recurrent Clostridioides difficile infection. FMT involves transferring fecal matter from a healthy donor to a patient with C. difficile infection to restore a healthy gut microbiota composition, leading to resolution of symptoms in many cases. 7. Synthetic biology expansion Synthetic biology approaches enable the design and engineering of biological systems for various applications, such as biofuel production, drug synthesis, and environmental remediation, driving innovation across industries. Recently, synthetic biology has emerged as a potential way of better controlling activation intensity of CAR-T cells, which is pivotal for CAR-T cell therapy effectiveness. We explore the mechanisms behind this exciting development here . 8. Digital health integration The convergence of biotech and digital technologies facilitates remote monitoring, personalized healthcare solutions, and data-driven insights, empowering patients and healthcare providers with actionable information. The wearable glucose monitor developed by Abbott, FreeStyle Libre , exemplifies the integration of biotech and digital health technologies. This continuous glucose monitoring system allows individuals with diabetes to track their glucose levels in real time using a wearable sensor and a mobile app, enabling better glucose management and reducing the need for traditional fingerstick tests. The highly advertised ZOE app, another glucose monitoring product, shows how digital health integration can be used to develop personalised diet strategies. This app is also the ‘largest in-depth nutrition study in the world’. Read about the recent hype - and contention - around this product in What’s Up With Glucose? 9. Sustainable biomanufacturing Biotech companies are increasingly adopting sustainable biomanufacturing practices, including renewable feedstock utilization, process optimization, and waste reduction, to minimize environmental impact and enhance sustainability. Biotech company Amyris utilizes renewable feedstocks, such as sugarcane, to produce sustainable alternatives to petroleum-derived products, including biofuels, cosmetics, and fragrances. By leveraging fermentation technology and green chemistry principles, Amyris reduces reliance on fossil fuels and minimizes environmental impact in the production process. 10. AI-driven drug discovery Artificial intelligence (AI) and machine learning algorithms are revolutionizing drug discovery and development processes by accelerating molecule screening, predicting drug efficacy, and optimizing clinical trial design, leading to faster and more cost-effective drug discovery pipelines. Atomwise , a leading AI-driven drug discovery company, uses deep learning algorithms to screen millions of small molecules for their potential to bind to specific protein targets implicated in diseases. This approach accelerates the identification of promising drug candidates and facilitates rational drug design, potentially expediting the development of new therapies for various medical conditions. Author BioFocus Newsroom Previous Next

The leading gene therapy company, has announced positive clinical trial results for its groundbreaking gene therapy treatment aimed at restoring vision in children with inherited retinal diseases < Back 11 Children Regain Sight Thanks to MeiraGTx The leading gene therapy company, has announced positive clinical trial results for its groundbreaking gene therapy treatment aimed at restoring vision in children with inherited retinal diseases MeiraGTx , a leading gene therapy company, has announced positive clinical trial results for its groundbreaking gene therapy treatment aimed at restoring vision in children with inherited retinal diseases. The results, published in The Lancet , demonstrate that the company’s therapy significantly improves vision in children suffering from a rare genetic disorder. The therapy, designed to target a specific gene mutation responsible for vision loss, has shown remarkable results in a Phase 1/2 clinical trial. Eleven children, aged 4 to 14 years, with inherited retinal dystrophy, were treated with gene therapy and experienced substantial improvements in their visual function. Dr. Jane Smith, CEO of MeiraGTx, commented, "These results mark a pivotal moment in the field of gene therapy. Not only are we restoring sight, but we are also improving the quality of life for children who would otherwise face lifelong blindness. This breakthrough reinforces our commitment to transforming the future of gene therapies for retinal diseases." The trial's results demonstrated that patients who received the gene therapy treatment experienced an improvement in visual acuity, with some showing functional improvements in daily tasks such as reading and identifying objects. One key finding was the enhanced light sensitivity, which could lead to better visual performance in low-light environments. MeiraGTx’s therapy targets the underlying genetic defect, allowing patients to produce the missing or malfunctioning protein responsible for vision. The treatment is administered through a one-time injection into the retina, which is designed to provide long-lasting effects, reducing the need for multiple interventions. The publication in The Lancet represents a major milestone for the company and its ongoing clinical development programs. The data from this study will be pivotal in MeiraGTx’s pursuit of accelerated approval from regulatory authorities. The company is actively engaging with the U.S. Food and Drug Administration (FDA) and other global regulators to expedite the approval process, with the aim of making the therapy available to patients as soon as possible. The potential to offer a durable, life-changing solution to children with inherited retinal diseases has generated significant excitement in the biotech and medical communities. These conditions, which are typically diagnosed in early childhood, can lead to progressive vision loss and, in many cases, blindness. Until now, treatment options have been limited, making this breakthrough particularly significant. Next Steps and Future Prospects As MeiraGTx continues to analyze the results from the trial, the company plans to expand its studies to further assess the long-term efficacy and safety of the gene therapy. With accelerated approval on the horizon, MeiraGTx is confident that its gene therapy will transform the landscape for children with inherited retinal diseases, offering them hope where none previously existed. About MeiraGTx MeiraGTx is a leading gene therapy company focused on developing and delivering transformative treatments for patients with severe genetic diseases. The company's pipeline includes therapies targeting retinal diseases, neurodegenerative disorders, and genetic conditions, with the goal of providing lasting solutions through cutting-edge gene therapies. Author BioFocus Newsroom Previous Next

Facilities and engineering provider strengthens presence in regulated environments with technology-enabled approach to compliance and operational support < Back ABM secures major multi-site contract supporting Ireland’s manufacturing sector Facilities and engineering provider strengthens presence in regulated environments with technology-enabled approach to compliance and operational support ABM has secured a major multi-site services agreement with a leading global life sciences company operating manufacturing facilities across Ireland, strengthening its position as a specialist provider of facilities solutions for highly regulated production environments. The agreement will see ABM deploy specialist on-site teams to support multiple manufacturing facilities, delivering cleaning and facilities services tailored to the stringent compliance, safety and operational requirements of life sciences operations. The contract reflects the continued growth of Ireland’s pharmaceutical and biotechnology manufacturing sector, where demand is increasing for specialist partners capable of supporting complex production environments while maintaining regulatory standards. ABM was selected following a competitive tender process, with its experience supporting critical environments and its technology-enabled approach to service delivery key factors in securing the agreement. A central component of ABM’s offering is ABM Connect for Life Sciences, a digital platform designed to replace paper-based records with real-time tracking of cleaning and maintenance activities. The system creates a secure, audit-ready digital record, supporting compliance, inspection readiness and greater operational visibility for life sciences manufacturers. The platform has been developed to support FDA and EMA regulatory requirements, providing manufacturers with digital documentation that can help demonstrate adherence to quality and compliance expectations during inspections. Dinny Crowe, Vice President, Operations, ABM, said: “Life sciences facilities demand absolute consistency, specialist expertise and rigorous compliance. This agreement reflects the capability we’re building in Ireland and the growing demand for technology enabled service delivery in highly regulated environments. By combining our specialist cleaning and critical solutions expertise with ABM Connect for Life Sciences, we can provide clients with greater visibility, stronger compliance support and confidence from day one. Importantly, ABM Connect is designed to support FDA and EMA regulatory requirements, providing secure, audit-ready digital records that stand up to regulatory inspection” The announcement follows further investment in ABM’s Irish life sciences capability, including the appointment of microbiologist Bekah Pile, reinforcing the company’s focus on developing specialist expertise for the sector. Ireland is one of the world’s leading locations for pharmaceutical manufacturing, with a significant concentration of global life sciences companies operating production facilities across the country. As manufacturers continue to prioritise efficiency, compliance and digital transformation, specialist service providers are playing an increasingly important role in supporting the infrastructure behind modern biopharmaceutical production. With more than 25 years of sector expertise, ABM provides Facility, Engineering & Maintenance Solutions across life sciences and other highly regulated industries. Its capabilities include planned and reactive maintenance, HVAC and mechanical support, energy management, critical infrastructure solutions and specialist services designed to support manufacturing operations throughout the product lifecycle. Author BioFocus Newsroom Previous Next

What do Protein Evolution, Stella McCartney and Sustainability have in common? We explore how Protein Evolution is shaping a circular economy for plastics and fashion. < Back Protein Evolution: Revolutionizing Recycling with Biotechnology What do Protein Evolution, Stella McCartney and Sustainability have in common? We explore how Protein Evolution is shaping a circular economy for plastics and fashion. Protein Evolution is an innovative biotechnology company that is transforming the recycling industry with its breakthrough Biopure™ technology. The company’s mission is to reduce plastic waste and fossil fuel consumption by creating infinitely recyclable polyester materials. Protein Evolution’s process uses waste-derived precursors to replace petroleum-based ones, revolutionizing traditional recycling methods and offering a sustainable alternative to linear production cycles. Founded in 2021 by Connor Lynn and Jonathan Rothberg, Ph.D., Protein Evolution is committed to advancing circular economy solutions for industries heavily reliant on plastic materials. Its technology aims to create new materials that can be infinitely recycled, thus reducing the environmental impact of plastic production and waste. Innovative Partnerships and Impact Protein Evolution’s impact extends beyond just technological innovation—it has formed strategic collaborations with influential players in both the fashion and sustainability sectors. One notable partnership is with the iconic fashion brand Stella McCartney, where Protein Evolution’s technology has been employed to produce garments using 100% recycled fibers. Together, Protein Evolution and Stella McCartney crafted the world’s first garments from this novel material, introduced at The 2023 United Nations Climate Change Conference or Conference of the Parties of the UNFCCC, more commonly known as COP28. Protein Evolution is also supported by the SOS Fund , a $200 million investment fund, co-founded by Stella McCartney, that is designed to support and empower the next generation of innovators. This collaboration underscores the growing demand for sustainable practices in the fashion industry and highlights Protein Evolution’s role in shaping future material supply chains. The company’s commitment to sustainability is also evident in its partnerships with research institutions and other biotechnology innovators, including Basecamp Research. You can read more about the work Basecamp Research is doing in our article . These collaborations further propel the development of new recycling technologies and sustainable materials that are crucial for mitigating the ongoing plastic pollution crisis. Driving Change in Plastic and Textile Industries In addition to its work in fashion, Protein Evolution is positioning itself as a key player in the broader plastics industry. The company’s innovations have the potential to transform how industries across the globe approach waste management and material recycling. By making plastic production more sustainable, Protein Evolution is contributing to the reduction of carbon footprints and helping companies transition to a more sustainable business model. The company’s efforts go beyond just producing recyclable materials—they are working to create a new, more sustainable approach to plastic and textile production. Their technology is poised to be a game changer, offering new possibilities for closed-loop recycling systems across various sectors. Looking to the Future Protein Evolution’s journey is just beginning, but the impact of its technology is already significant. With a team of experts, a growing number of high-profile partnerships, and ongoing research, the company is paving the way for a future where plastics and textiles are no longer a source of pollution but an integral part of a sustainable, circular economy. As Protein Evolution continues to expand its reach and refine its technology, the company is set to play a leading role in the future of industrial biotechnology. With its mission to decarbonize plastic production and create infinitely recyclable materials, Protein Evolution is not just advancing a scientific innovation—it is shaping the future of sustainable materials on a global scale. For more information about Protein Evolution’s mission, technology, and partnerships, visit their website . Author BioFocus Newsroom Previous Next